Structure Therapeutics (GPCR) Operating Expenses (2022 - 2026)

Structure Therapeutics' Operating Expenses history runs 5 years deep, the most recent figure standing at $89.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 58.72% year-over-year to $89.4 million in Q1 2026; TTM through Mar 2026 was $209.6 million, a 14.85% increase from a year earlier, with the FY2025 full-year figure at $176.6 million, up 11.59% from the prior year.
• Operating Expenses climbed to $89.4 million in Q1 2026 per GPCR's latest filing, from -$24.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $89.4 million in Q1 2026 and bottomed at -$24.0 million in Q4 2025.
• The 5-year median for Operating Expenses is $31.0 million (2023), against an average of $34.1 million.
• Across the five-year window, Operating Expenses soared 139.23% in 2023 and slumped 150.97% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $13.0 million in 2022, then surged by 139.23% to $31.0 million in 2023, then surged by 51.84% to $47.1 million in 2024, then tumbled by 150.97% to -$24.0 million in 2025, then soared by 472.58% to $89.4 million in 2026.
• Per Business Quant, the three latest GPCR Operating Expenses figures stand at $89.4 million (Q1 2026), -$24.0 million (Q4 2025), and $73.8 million (Q3 2025).